

# TABLE OF CONTENTS

|   |           |
|---|-----------|
| <b>0. Executive Summary .....</b>   | <b>10</b> |
| <b>1. Basics of Transdermal Drug Delivery .....</b>                         | <b>12</b> |
| <b>Introduction .....</b>   | <b>12</b> |
| Historical landmarks in transdermal drug delivery .....                     | 12        |
| <b>Anatomy and physiology of skin .....</b>                                 | <b>13</b> |
| Transcutaneous absorption .....   | 13        |
| <b>Transdermal versus other methods of drug delivery .....</b>              | <b>13</b> |
| Advantages of transdermal drug delivery .....                               | 14        |
| <i>First-Pass Effect</i> .....  | 14        |
| Drawbacks of transdermal delivery .....                                     | 14        |
| <b>Factors that influence transdermal drug delivery .....</b>               | <b>14</b> |
| <b>Events governing transcutaneous absorption .....</b>                     | <b>15</b> |
| Properties of the skin .....  | 15        |
| Properties of drugs .....   | 16        |
| <i>The role of pH and pharmacokinetics</i> .....                            | 16        |
| <i>Intradermal disposition of drugs after topical application</i> .....     | 17        |
| <b>2. Transdermal Drug Delivery Technologies .....</b>                      | <b>18</b> |
| <b>Introduction .....</b>   | <b>18</b> |
| <b>Local application formulations .....</b>                                 | <b>19</b> |
| Crystalline topical formulations .....                                      | 19        |
| Microemulsions for transdermal drug delivery .....                          | 19        |
| Transdermal gel technology .....  | 20        |
| Film forming polymeric solutions .....                                      | 21        |
| Biphasic system .....   | 21        |
| <b>Penetration enhancers .....</b>  | <b>22</b> |
| Chemical enhancers .....  | 22        |
| <i>Nitric oxide-based transdermal drug delivery</i> .....                   | 24        |
| Vesicular transdermal carriers .....  | 24        |
| <i>Liposomes</i> .....  | 24        |
| <i>Transfersomes</i> .....  | 25        |
| <i>Ethosomes</i> .....  | 25        |
| <i>Elastic vesicles for transdermal drug delivery</i> .....                 | 26        |
| <i>Nanovesicles for transdermal drug delivery</i> .....                     | 26        |
| <b>Transdermal patches .....</b>  | <b>27</b> |
| Adhesives for transdermal patches .....                                     | 28        |
| Commercial development of transdermal patches .....                         | 28        |
| Innovations in transdermal patches .....                                    | 29        |
| <i>e-Patch™ controlled release micropump system</i> .....                   | 29        |
| <i>Patchless Transdermal Delivery System</i> .....                          | 30        |
| <i>Metered-dose transdermal system</i> .....                                | 30        |
| <b>Use of physical modalities to facilitate transdermal transport .....</b> | <b>31</b> |
| Transdermal electrotransport .....  | 31        |
| Electroporation .....   | 31        |
| <i>Drug delivery by electroporation</i> .....                               | 32        |
| Cryoelectrophoresis .....   | 33        |
| Iontophoresis .....   | 34        |
| <i>Iontophoresis compared with electrophoresis</i> .....                    | 35        |
| <i>Application of iontophoresis for drug delivery</i> .....                 | 35        |
| <i>Companies with technologies for drug delivery by iontophoresis</i> ..... | 36        |
| Combination of electrophoresis and iontophoresis .....                      | 37        |
| <i>Dermaportation</i> .....   | 37        |
| Radiofrequency-driven transdermal delivery .....                            | 37        |
| Microporation .....   | 38        |
| Transcutaneous drug delivery by electropulsation .....                      | 38        |
| Companies involved in electroporation-based drug delivery .....             | 39        |
| Electrode Scanning System .....   | 39        |
| Use of electrostatic force in skin patch technology .....                   | 39        |
| Multiple Absorption Kinetic System .....                                    | 40        |
| Transdermal drug delivery facilitated by heat .....                         | 40        |
| <i>Controlled, heat-aided drug delivery</i> .....                           | 40        |
| Ultrasound .....  | 41        |
| Magnetophoresis .....   | 42        |
| Use of lasers for transdermal drug delivery .....                           | 42        |
| <i>Transdermal drug delivery by laser-induced pressure waves</i> .....      | 42        |
| <i>Transdermal drug delivery by laser-assisted changes in skin</i> .....    | 43        |

|   |           |
|---|-----------|
| Transdermal delivery by gas under pressure .....                                  | 44        |
| <i>Transdermal delivery with PowderJect gas gun</i> .....                         | 44        |
| <i>Microscission induced by gas</i> .....   | 44        |
| <b>Microneedles and dermal microinjection technologies</b> .....                  | <b>44</b> |
| Microneedle patch .....   | 44        |
| Microneedle arrays for drug delivery.....   | 45        |
| MicroPyramid™ hollow microneedles .....   | 46        |
| Microstructured Transdermal Systems .....   | 46        |
| Microneedle Array Patch technology .....  | 46        |
| Macroflux microprojections technology .....                                       | 47        |
| Companies developing microneedles for transdermal drug delivery .....             | 47        |
| <b>Needlefree injections</b> .....  | <b>47</b> |
| Glide SDI® solid dose injector.....   | 47        |
| Jet injection .....   | 48        |
| Mini-Ject needlefree delivery system .....  | 48        |
| MicroJet for painless injections .....  | 48        |
| Nanoliter-volume pulsed microjets .....   | 49        |
| SUMAVEL™ DosePro™ needle-less injection .....                                     | 49        |
| <b>Skin ablation or abrasion for drug delivery</b> .....                          | <b>49</b> |
| <b>Nanotechnology-based transdermal drug delivery</b> .....                       | <b>50</b> |
| Nanoparticles and nanoemulsions for skin disorders .....                          | 50        |
| Transdermal nanoparticle preparations for systemic effect .....                   | 50        |
| Nanotechnology-based transdermal vaccination and immunotherapy.....               | 51        |
| Delivery of nanostructured drugs from transdermal patches .....                   | 52        |
| NanoCyte transdermal drug delivery system .....                                   | 52        |
| Effect of mechanical flexion on penetration of bucky balls through the skin ..... | 52        |
| Safety issues of applications of nanomaterial carriers on the skin.....           | 52        |
| <b>Comparison of transdermal drug delivery systems</b> .....                      | <b>53</b> |
| <b>Role of microelectronics in transdermal drug delivery</b> .....                | <b>53</b> |
| <b>Transdermal drug design</b> .....  | <b>53</b> |
| <b>In vitro testing of transdermal drug delivery systems</b> .....                | <b>54</b> |
| <b>In vivo testing of drug delivery systems</b> .....                             | <b>55</b> |
| Infrared spectroscopy for evaluation of transdermal drug delivery.....            | 55        |
| <b>Modeling of transport through the skin</b> .....                               | <b>55</b> |
| <b>Concluding remarks on transdermal drug delivery technologies</b> .....         | <b>56</b> |
| <b>Future developments in transdermal drug delivery</b> .....                     | <b>57</b> |

|  |           |
|--|-----------|
| <b>3. Transdermal Therapeutics</b> .....                                       | <b>58</b> |
| <b>Introduction</b> .....  | <b>58</b> |
| <b>Drugs that can be administered transdermally</b> .....                      | <b>58</b> |
| <b>Skin disorders</b> .....  | <b>61</b> |
| Fungus infections of nails.....  | 61        |
| <i>Topical penetrating applications for nail fungus infections</i> .....       | 61        |
| Hair loss .....  | 61        |
| <b>Cardiovascular disorders</b> .....  | <b>61</b> |
| Angina pectoris.....   | 61        |
| Transdermal drug delivery for hypertension .....                               | 63        |
| Transdermal beta blockers .....  | 63        |
| Transdermal anticoagulants .....   | 63        |
| Congestive heart failure.....  | 64        |
| <b>Respiratory diseases</b> .....  | <b>64</b> |
| Asthma.....  | 64        |
| Chronic obstructive pulmonary disease .....                                    | 65        |
| <b>Neurological and psychiatric disorders</b> .....                            | <b>65</b> |
| Parkinson's disease .....  | 65        |
| <i>Transdermal drug delivery for Parkinson's disease</i> .....                 | 66        |
| <i>Transdermal dopamine agonists for Parkinson's disease</i> .....             | 66        |
| <i>Rotigotine</i> .....  | 67        |
| <i>Transdermal administration of other drugs for Parkinson's disease</i> ..... | 68        |
| Depression.....  | 68        |
| <i>Transdermal selegiline</i> .....  | 68        |
| Bipolar disorder .....   | 69        |
| <i>Transdermal lithium</i> .....   | 69        |
| Restless legs syndrome .....   | 69        |
| Alzheimer's disease.....   | 70        |
| Transdermal nicotine for Tourette syndrome .....                               | 70        |
| Attention deficit hyperactivity disorder.....                                  | 70        |
| <i>Transdermal methylphenidate</i> .....                                       | 70        |
| Migraine .....   | 71        |
| <i>Transdermal lidocaine</i> .....   | 71        |
| <i>Transdermal sumatriptan</i> .....   | 71        |

|   |           |
|---|-----------|
| Epilepsy.....   | 71        |
| Tinnitus/Vertigo.....   | 72        |
| Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage..... | 72        |
| <b>Musculoskeletal disorders.....</b>                                       | <b>72</b> |
| Osteoporosis.....   | 72        |
| <i>Transdermal hormonal therapy.....</i>                                    | <i>73</i> |
| Osteoarthritis.....   | 73        |
| <b>Transdermal insulin delivery in diabetes.....</b>                        | <b>73</b> |
| <b>Male sexual disorders.....</b>   | <b>74</b> |
| Erectile dysfunction.....   | 74        |
| <i>Topical and transdermal preparation for erectile dysfunction.....</i>    | <i>75</i> |
| Hypogonadism in the male.....   | 75        |
| <i>Topical testosterone.....</i>  | <i>76</i> |
| <b>Women's health.....</b>  | <b>77</b> |
| Female sexual arousal disorder.....   | 77        |
| Menopause.....  | 78        |
| <i>Hormone replacement therapy for menopause.....</i>                       | <i>78</i> |
| <i>Effect of transdermal estradiol on bone density.....</i>                 | <i>80</i> |
| <i>Transdermal testosterone for low libido in postmenopausal women.....</i> | <i>80</i> |
| Breast disorders.....   | 80        |
| Dysmenorrhea.....   | 81        |
| <b>Contraception.....</b>   | <b>81</b> |
| Female contraception.....   | 81        |
| <i>Ortho Evra™.....</i>   | <i>81</i> |
| <i>BAY86-5016.....</i>  | <i>82</i> |
| Male contraception.....   | 82        |
| <i>Transdermal progestin plus testosterone.....</i>                         | <i>82</i> |
| <b>Cancer.....</b>  | <b>83</b> |
| Transcutaneous electroporation for anticancer drugs.....                    | 83        |
| Transdermal nitroglycerine for prostate cancer.....                         | 83        |
| <b>Pain.....</b>  | <b>84</b> |
| Relief of pain associated with minor medical procedures.....                | 84        |
| Transdermal Lidoderm® for postherpetic neuralgia.....                       | 84        |
| Nonsteroidal antiinflammatory drugs.....                                    | 85        |
| <i>Topical NSAIDs.....</i>  | <i>85</i> |
| <i>Transdermal ketoprofen.....</i>  | <i>86</i> |
| <i>Topical opioids.....</i>   | <i>87</i> |
| Cancer pain.....  | 87        |
| <i>Transdermal fentanyl.....</i>  | <i>87</i> |
| <i>Transdermal nitroglycerine as an adjuvant to opioids.....</i>            | <i>88</i> |
| <i>Transdermal buprenorphine.....</i>                                       | <i>88</i> |
| Chronic pain of non-malignant origin.....                                   | 89        |
| Postoperative pain.....   | 89        |
| <i>Transdermal fentanyl for the management of postoperative pain.....</i>   | <i>89</i> |
| <i>Fibromyalgia.....</i>  | <i>89</i> |
| <b>Nausea and vomiting.....</b>   | <b>90</b> |
| Motion sickness.....  | 90        |
| Postoperative vomiting.....   | 90        |
| Chemotherapy-induced nausea and vomiting.....                               | 90        |
| <b>Antiaging strategies.....</b>  | <b>90</b> |
| <b>Smoking cessation.....</b>   | <b>91</b> |
| Transdermal nicotine replacement.....                                       | 91        |
| Other methods of nicotine replacement.....                                  | 92        |
| Other treatments for smoking cessation.....                                 | 92        |
| <b>Miscellaneous uses of transdermal drug delivery.....</b>                 | <b>93</b> |
| Chronic fatigue syndrome.....   | 93        |
| <i>Topical androgenic steroid therapy.....</i>                              | <i>93</i> |
| Overactive bladder and urinary incontinence.....                            | 93        |
| <i>Transdermal oxybutynin.....</i>  | <i>93</i> |
| Viral infections.....   | 94        |
| <i>Transdermal nanoparticles for immune enhancement in HIV.....</i>         | <i>94</i> |
| <b>Transdermal gene therapy.....</b>  | <b>94</b> |
| Transdermal delivery of plasmid DNA by electroporation.....                 | 95        |
| <b>Transdermal antisense therapy.....</b>                                   | <b>95</b> |
| <b>Transdermal vaccination.....</b>   | <b>96</b> |
| The skin as an immune organ.....  | 96        |
| Technologies for transdermal vaccination.....                               | 96        |
| <i>Dermal microinjection technology for delivery of vaccines.....</i>       | <i>96</i> |
| <i>Electroporation for administering DNA vaccines.....</i>                  | <i>96</i> |
| <i>Intradermal delivery of cancer vaccines by adenoviral vectors.....</i>   | <i>97</i> |
| <i>Needle free delivery of vaccines.....</i>                                | <i>97</i> |

|  |            |
|--|------------|
| <i>Transcutaneous immunization</i> .....   | 98         |
| Applications of transdermal vaccination .....                                    | 98         |
| <i>HIV/AIDS vaccination by topical application</i> .....                         | 98         |
| <i>Transdermal DNA influenza vaccine</i> .....                                   | 99         |
| <i>Transdermal A<math>\beta</math> vaccination for Alzheimer's disease</i> ..... | 99         |
| <i>Transdermal vaccination for traveller's diarrhoea</i> .....                   | 99         |
| Transdermal neutraceuticals.....   | 100        |
| <b>Complications of transdermal therapy</b> .....                                | <b>100</b> |
| Adverse effects of drugs .....   | 100        |
| Overdose effect .....  | 101        |
| Skin complications .....   | 101        |
| <b>4. Markets for Transdermal Drug Delivery</b> .....                            | <b>102</b> |
| <b>Introduction</b> .....  | <b>102</b> |
| <b>Global markets for drug delivery</b> .....                                    | <b>102</b> |
| <b>Geographical distribution of transdermal drug delivery markets</b> .....      | <b>103</b> |
| Emerging transdermal drug delivery markets in Asia .....                         | 103        |
| <b>Transdermal technology markets in therapeutic areas</b> .....                 | <b>103</b> |
| Angina pectoris.....   | 104        |
| Attention deficit hyperactivity disorder.....                                    | 104        |
| Erectile dysfunction.....  | 104        |
| Hypertension.....  | 105        |
| Pain therapeutics .....  | 105        |
| Parkinson's disease .....  | 105        |
| Smoking cessation .....  | 105        |
| Transdermal hormone replacement therapy for menopause .....                      | 105        |
| Transdermal testosterone replacement therapy for hypogonadism in the male .....  | 106        |
| Transdermal contraceptive market.....  | 106        |
| <b>Markets according to transdermal technologies</b> .....                       | <b>106</b> |
| <b>Marketing strategies for transdermal drug delivery</b> .....                  | <b>106</b> |
| <b>Marketing advantages of transdermal drug delivery</b> .....                   | <b>107</b> |
| <b>Unmet needs in transdermal drug delivery</b> .....                            | <b>108</b> |
| <b>Future prospects of transdermal drug delivery</b> .....                       | <b>109</b> |
| Prospects of transdermal delivery for drugs coming off patents.....              | 109        |
| Transdermal delivery of cosmetics .....  | 109        |
| <b>5. Companies involved in transdermal drug delivery</b> .....                  | <b>110</b> |
| <b>Profiles of companies</b> .....   | <b>110</b> |
| <b>Collaborations</b> .....  | <b>231</b> |
| <b>6. References</b> .....   | <b>236</b> |

## Tables

|   |     |
|---|-----|
| Table 1-1: Historical landmarks in the development of transdermal drug delivery .....   | 12  |
| Table 1-2: Transdermal vs oral and intravenous drug delivery .....                      | 14  |
| Table 2-1: Technologies for transdermal drug delivery .....                             | 18  |
| Table 2-2: Chemical enhancers of skin penetration .....                                 | 22  |
| Table 2-3: Drug-in-adhesive versus reservoir type of transdermal patch.....             | 27  |
| Table 2-4: Companies developing transdermal patches for drug delivery .....             | 28  |
| Table 2-5: Companies with technologies for drug delivery by iontophoresis.....          | 36  |
| Table 2-6: Companies involved in electroporation-based drug delivery .....              | 39  |
| Table 2-7: Companies developing microneedles for transdermal drug delivery.....         | 47  |
| Table 2-8: Comparison of transdermal drug delivery systems.....                         | 53  |
| Table 3-1: Approved categories of transdermal drugs.....                                | 58  |
| Table 3-2: Current status of transdermal products .....                                 | 59  |
| Table 4-1: Worldwide drug delivery market growth 2009 to 2019 .....                     | 102 |
| Table 4-2: Transdermal drug delivery markets for geographical regions 2009 to 2019..... | 103 |
| Table 4-3: Potential therapeutic markets for transdermal products 2009-2019 .....       | 104 |
| Table 4-4: Marketing strategies based on transdermal drug delivery technologies.....    | 107 |
| Table 5-1: Collaborations in transdermal drug delivery .....                            | 231 |

## Figures

|  |    |
|--|----|
| Figure 1-1: Basic structure of the skin.....                                       | 13 |
| Figure 1-2: Events governing transcutaneous drug absorption .....                  | 16 |
| Figure 2-1: Basic structure and function of transdermal drug delivery systems..... | 27 |
| Figure 2-2: A schematic view of electroporation.....                               | 32 |

|   |     |
|---|-----|
| Figure 2-3: Depiction of breakdown of the stratum corneum during electroporation .....    | 33  |
| Figure 2-4: A schematic drawing of Iontophoresis.....                                     | 34  |
| Figure 2-5: SonoPrep ultrasonic skin permeation .....                                     | 41  |
| Figure 2-6: A schematic drawing of the microneedle patch.....                             | 45  |
| Figure 3-1: Oral versus transdermal administration of a drug in Parkinson's disease ..... | 67  |
| Figure 4-1: Unmet needs in transdermal drug delivery .....                                | 108 |